In the Union Budget 2026, Union Finance Minister Nirmala Sitharaman proposed ‘Biopharma SHAKTI’ to develop India as a global bio-pharma manufacturing hub. It will have an outlay of Rs 10,000 crores over the next five years.
Union Finance Minister Nirmala Sitharaman (Photo: IANS/Video Grab/Sansad TV)
In the Union Budget 2026, Union Finance Minister Nirmala Sitharaman proposed ‘Biopharma SHAKTI’ to develop India as a global bio-pharma manufacturing hub. It will have an outlay of Rs 10,000 crores over the next five years. The Finance Minister stressed that this will help in building an ecosystem for domestic production of biologics and biosimilars.
SHAKTI stands for Strategy for Healthcare Advancement through Knowledge, Technology & Innovation. The proposal says that Biopharma SHAKTI will allow building an ecosystem for domestic production of biologics and biosimilars. It will include a Biopharma-focused network with three new National Institutes of Pharmaceutical Education and Research and upgrading seven existing ones. It will be dedicated to create network of over 1000 accredited Indian Clinical Trials sites.
Advertisement
Advertisement
Nirmala Sitharaman said, “Scaling up manufacturing in seven strategic and frontier sectors: Biopharma Shakti, meaning a biopharma strategy for health advancement through knowledge, technology, and innovation. India’s disease burden is observed to be shifting towards non-communicable diseases like diabetes, cancer, and autoimmune disorders…”
Delhi: Union Finance Minister Nirmala Sitharaman says, “Scaling up manufacturing in seven strategic and frontier sectors: Biopharma Shakti, meaning a biopharma strategy for health advancement through knowledge, technology, and innovation. India’s disease burden is observed to be… pic.twitter.com/ZogL8Mo0kG
— IANS (@ians_india) February 1, 2026
Advertisement
